Daraxonrasib Pill Doubles Survival in Deadliest Cancer
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Daraxonrasib – a daily pill – can double survival time in patients with the world’s deadliest cancer, according to clinical trial results.
- The clinical trial reported the survival benefit and is being hailed as a game‑changer and one of the biggest breakthroughs in decades.
- Prof Naureen Starling, consultant medical oncologist at Royal Marsden hospital, explains how daraxonrasib works in the podcast.
- Madeleine Finlay hosts the Guardian sciencepod episode discussing the treatment’s life‑changing potential.
- The Guardian offers the podcast under its sciencepod series.
Why it matters: Patients with the world’s deadliest cancer gain potentially double the lifespan, while clinicians acquire a first effective oral therapy for a disease long deemed untreatable, reshaping treatment protocols and offering hope where few options existed. The breakthrough also challenges the notion that certain cancers are undruggable, prompting pharmaceutical firms to invest in similar targets.
Ask SkimNews
